Publications by authors named "I Hashida"
We compared clinical outcomes associated with seed brachytherapy (SEED-BT) alone and SEED-BT plus external-beam radiotherapy (EBRT) for intermediate-risk prostate cancer using propensity score-matched analysis. From 2006 to 2011, 993 patients diagnosed with intermediate-risk were treated with either SEED-BT alone (n = 775) or SEED-BT plus EBRT (n = 158) at 3 tertiary hospitals. In the propensity score-matched analysis (102 pairs), median follow-up was 95 months (range 18-153 months).
View Article and Find Full Text PDFBackground: We compared the oncological outcomes of patients who received seed brachytherapy (SEED-BT) with those who received radical prostatectomy (RP) for intermediate-risk prostate cancer.
Methods: Candidates were patients treated with either SEED-BT (n = 933) or RP (n = 334). One-to-one propensity score matching was performed to adjust the patients' backgrounds.
Article Synopsis
- The study aimed to evaluate how effective tadalafil is at reducing negative side effects in prostate cancer patients after they undergo low-dose-rate brachytherapy compared to tamsulosin.
- It was a year-long randomized trial involving 107 patients, focusing on urinary symptoms and sexual health, tracked through various assessments.
- Results showed that while tadalafil didn't significantly improve urinary symptoms overall, it did lead to better sexual health scores compared to tamsulosin, suggesting it could be a beneficial option post-treatment.*
A total of 320 localized prostate cancer patients including 272 at low-risk and 48 at intermediate-risk were treated with permanent iodine-125 seed implants. Changes of lower urinary tract symptoms after the treatment were analyzed for one consecutive year using international prostate symptom score, quality of life (QOL) score and uroflowmetry. These patients did not have prostate hypertrophy or were not treated with any α1 blocker before the seed implant.
View Article and Find Full Text PDFObjective: To evaluate the initial results of brachytherapy for prostate cancer with permanent iodine-125 implant in Japan.
Methods: The results obtained with brachytherapy in the initial 100 Japanese patients treated at Nagano Municipal Hospital were reviewed. Patients with a prostate-specific antigen (PSA) level of less than 10 ng/mL and a Gleason's scores of 5, 6, 3 + 4 were classified as having a low risk of recurrence.